Gastroenteropancreatic Neuroendocrine Tumors Recruiting Phase 1 Trials for Dotatate gallium Ga-68 (DB13925)

Back to Gastroenteropancreatic Neuroendocrine Tumors

Also known as: Gastro-entero-pancreatic Neuroendocrine Tumor / Gastro-entero Pancreatic Neuroendocrine Tumors / Gastro Entero Pancreatic Neuroendocrine Tumors / Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) / Neuroendocrine Gastroenteropancreatic Tumour / Gastro-entero-pancreatic Neuroendocrine Tumors / GEP-NET / Gastro-enteropancreatic Neuroendocrine Tumor / Gastro-Entero-Pancreatic Tumors (GEPs) / Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) / Neuroendocrine Tumors,Gastroenteropancreatic / Gastroenteral-Pancreatic Neuroendocrine Tumors / Gastroenteropancreatic Neuroendocrine Tumours / Gastroenteropancreatic Neuroendocrine Tumor / Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) / Gastroenteropancreatic Neuroendocrine Tumor Disease / Gep Net / Gastroenteropancreatic neuroendocrine tumour disease

Indication	Status	Phase
DBCOND0063370 (Gastroenteropancreatic Neuroendocrine Tumors)	Recruiting	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT04609592	Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery	Treatment	Dotatate gallium Ga-68 (DB13925) Lutetium Lu 177 dotatate (DB13985)